Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments

Neuroendocrinology Letters

Volumn 35, Issue 2, 2014, Pages 104-109

  Li, Weiyun ^a   Ling, Shucai ^a   Yang, Yang ^a   Hu, Zhiying ^b   Davies, Henry ^a   Fang, Marong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Hangzhou Red Cross Hospital   (China)

Author keywords

Inflammation; Neurotransmission; Neurotrophins; Post stroke depression; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CITALOPRAM; CYTOKINE; DOPAMINE; FLUOXETINE; GLUCOCORTICOID; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIN; NORADRENALIN; PINDOLOL; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; STRESS HORMONE; SUCROSE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANTIDEPRESSANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN; BRAIN ISCHEMIA; CELL DEATH; CELL SURVIVAL; CELL THERAPY; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CYTOKINE PRODUCTION; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MEDICATION COMPLIANCE; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE CELL CULTURE; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; POSTSTROKE DEPRESSION; PROTEIN FUNCTION; RISK REDUCTION; SIGNAL TRANSDUCTION; STRESS; STROKE PATIENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; ENCEPHALITIS; GLUTAMIC ACID; HUMANS; INFLAMMATION MEDIATORS; NERVE GROWTH FACTORS; NEURAL STEM CELLS; STROKE; SYNAPTIC TRANSMISSION;

EID: 84903194329     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Acler M, Robot E, Fiaschi A, Manganotti P (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol 256: 1152-1158.
2. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, et al. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26: 607-611.
3. Allan SM, Rothwell NJ (2001). Cytokines and acute neurodegeneration. Nature Reviews Neuroscience 2: 734-744. (Pubitemid 33674819)
4. Anisman H, Hayley S (2012). Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal 5: pe45.
5. Anisman H, Kokkinidis L, Merali Z (2002). Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 16: 544-556. (Pubitemid 35333734)
6. Chollet F, Tardy J, Albucher J-F, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, et al. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebocontrolled trial. The Lancet Neurology 10: 123-130.
7. Chung YC, Kim SR, Jin BK (2010). Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. The Journal of Immunology 185: 1230-1237.
8. Chung YC, Kim SR, Park J-Y, Chung ES, Park KW, Won SY, Bok E, Jin M, et al. (2011). Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60: 963-974.
9. Dantzer R, O'connor JC, Lawson MA, Kelley KW (2011). Inflammation- associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36: 426-436.
10. Doetsch F (2003). A niche for adult neural stem cells. Current Opinion in Genetics & Development 13: 543-550.
11. El Hachioui H, Lingsma HF, Van De Sandt-Koenderman MW, Dippel DW, Koudstaal PJ, Visch-Brink EG (2013). Long-term prognosis of aphasia after stroke. Journal of Neurology, Neurosurgery & Psychiatry 84: 310-315.
12. Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Bührer C, Stahel PF (2005). IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci 28: 487-493. (Pubitemid 41187798)
13. Feldmann Jr RE, Mattern R (2006). The human brain and its neural stem cells postmortem: from dead brains to live therapy. Int J Legal Med 120: 201-211.
14. Franklin TB, Saab BJ, Mansuy IM (2012). Neural mechanisms of stress resilience and vulnerability. Neuron 75: 747-761.
15. Grau AJ, Reis A, Buggle F, Al-Khalaf A, Werle E, Valois N, Bertram M, Becher H, et al. (2001). Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 192: 41-47. (Pubitemid 32999022)
16. Ising M, Künzel HE, Binder EB, Nickel T, Modell S, Holsboer F (2005). The combined dexamethasone/CRH test as a potential surrogate marker in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29: 1085-1093. (Pubitemid 41080135)
17. Jorge RE, Acion L, Moser D, Adams Jr HP, Robinson RG (2010). Escitalopram and enhancement of cognitive recovery following stroke. Archives of general psychiatry 67: 187.
18. Jorge RE, Robinson RG, Arndt S, Starkstein S (2003). Mortality and poststroke depression: a placebo-controlled trial of antidepressants. American journal of Psychiatry 160: 1823-1829. (Pubitemid 41103317)
19. Keller MB, Hirschfeld R, Demyttenaere K, Baldwin D (2002). Optimizing outcomes in depression: focus on antidepressant compliance. International clinical psychopharmacology 17: 265-271. (Pubitemid 35283713)
20. Koch P, Kokaia Z, Lindvall O, Brüstle O (2009). Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. The Lancet Neurology 8: 819-829.
21. Kostulas N, Pelidou SH, Kivisäkk P, Kostulas V, Link H (1999). Increased IL-1β, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 30: 2174-2179. (Pubitemid 29473266)
22. Kumar B, Kuhad A, Chopra K (2011). Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences. Psychopharmacology (Berl) 214: 819-828.
23. Lang U, Borgwardt S (2013). Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cellular Physiology and Biochemistry 31: 761-777.
24. Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L, Popa-Wagner A (2012). Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med 16: 1961-1969.
25. Madri J (2009). Modeling the neurovascular niche: implications for recovery from CNS injury. J Physiol Pharmacol 60: 95-104.
26. Maes M, Leonard B, Myint A, Kubera M, Verkerk R (2011). The new '5-HT'hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Progress in Neuro- Psychopharmacology and Biological Psychiatry 35: 702-721.
27. Narushima K, Paradiso S, Moser DJ, Jorge R, Robinson RG (2007). Effect of antidepressant therapy on executive function after stroke. The British Journal of Psychiatry 190: 260-265. (Pubitemid 46384011)
28. Numakawa T, Adachi N, Richards M, Chiba S, Kunugi H (2013). Brain-Derived Neurotrophic Factor and Glucocorticoids: Reciprocal Influence in the central nervous system. Neuroscience. 239: 157-72.
29. Oppenheim JJ, Yang D (2005). Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17: 359-365. (Pubitemid 40848537)
30. Portella MJ, De Diego-Adelino J, Ballesteros J, Puigdemont D, Oiler S, Santos B, Ivarez E, Artigas F, et al. (2011). Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a metaanalysis of pindolol in nonresistant depression. The Journal of clinical psychiatry 72: 962-969.
31. Pustokhanova L, Morozova E (2013). Cognitive impairment and hypothymia in post stroke patients. J Neurol Sci. 325(1-2): 43-5.
32. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, et al. (2008). Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA: the journal of the American Medical Association 299: 2391-2400.
33. Sanacora G, Treccani G, Popoli M (2012). Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62: 63-77.
34. Semkova I, Krieglstein J (1999). Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain research reviews 30: 176-188. (Pubitemid 29440940)
35. Smith-Swintosky VL, Pettigrew LC, Sapolsky RM, Phares C, Craddock SD, Brooke SM, Mattson MP (1996). Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. Journal of Cerebral Blood Flow & Metabolism 16: 585-598. (Pubitemid 26227067)
36. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, Del Zoppo GJ, Hallenbeck JM, et al. (2004). Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC neurology 4: 2.
37. Spalletta G, Bossu P, daramella A, Bria P, Caltagirone C, Robinson R (2006). The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 11: 984-991. (Pubitemid 44631641)
38. Takahashi K, Yamanaka S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676. (Pubitemid 44233629)
39. Turnbull AV, Rivier CL (1999). Regulation of the hypothalamicpituitary- adrenal axis by cytokines: actions and mechanisms of action. Physiological reviews 79: 1-71. (Pubitemid 29056948)
40. Wang Q, Tang XN, Yenari MA (2007). The inflammatory response in stroke. J Neuroimmunol 184: 53-68. (Pubitemid 46365991)
41. Wang S, Zhang Z, Guo Y, Zhou H, Teng G, Chen B (2009). Anhedonia and activity deficits in rats: impact of post-stroke depression. J Psychopharmacol 23: 295-304.
42. Zhang Y, Pardridge WM (2006). Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res 1111: 227-229. (Pubitemid 44339581)
43. Zhang ZG, Chopp M (2009). Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. The Lancet Neurology 8: 491-500.